• ONC201 to be discussed at the Keystone Symposia on Molecular and Cellular Biology on February 20, 2018

    Josh Allen of Oncoceutics will be giving a Short Talk under the title of “Differentiated Receptor Pharmacology of Imipridone ONC201: The First DRD2 Antagonist in Clinical Development for Oncology”.

    The Short Talk is part of the Keystone Symposia on Molecular and Cellular Biology and will take place in a session named “Drug Discovery and the Realistic Process”.

    Please see below for more details:

    Josh Allen, Oncoceutics, USA: Short Talk: Differentiated Receptor Pharmacology of Imipridone ONC201: The First DRD2 Antagonist in Clinical Development for Oncology

    February 20, 2018 from 17:00—19:00 at the Eldorado Hotel & Spa, Santa Fe, New Mexico, USA (room: Eldorado Grand Ballroom)

Photostream